MaxCyte, Inc. (MXCT) Stock

About MaxCyte, Inc.

MaxCyte, Inc. is led by CEO Maher Masoud, employs 114 people, headquartered in US, publicly traded since 2021.

MaxCyte, Inc. (MXCT) stock trades at $1.40 with a market capitalization of $144.49M. The stock is valued at a negative price-to-earnings (P/E) ratio of -3.20, reflecting a net loss over the last twelve months, price-to-book of 0.72, price-to-sales of 3.69. Over the past 52 weeks the stock has ranged between $0.64 and $1.87, and currently trades 25.1% below its 52-week high.

On profitability, MaxCyte, Inc. generates a return on equity (ROE) of -21.01% (negative, reflecting a net loss), return on capital employed of -19.83%, an operating margin of -136.36%, a net profit margin of -114.77%.

MaxCyte, Inc. by the numbers, 2016–2025

Between 2016 and 2025 MaxCyte, Inc. reported revenue of $12.0M rising to $33.0M, a change of +175.0% across 10 years. Compounded, revenue has grown 4.9% a year over five years, -9.1% over three, -15.4% over the last twelve months. Net profit fell to $-45.0M.

Operating margin went from -22.2% in 2016 to -137.1% in 2025, a fall of 114.9 percentage points. The most recent net margin is -114.77%. On a trailing twelve-month basis to Jun '26, revenue is $31.0M and net profit $-36.0M.

Borrowings rose from $5.0M to $18.0M, cash from operations was $-34.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -15.8% over five years, and was -26.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

MaxCyte, Inc. (MXCT) — frequently asked questions